贝伐单抗联合化疗治疗非小细胞肺癌的临床研究.docVIP

精品论文 参考文献 贝伐单抗联合化疗治疗非小细胞肺癌的临床研究 张琳琳 　　（辽宁省肿瘤医院内五科 辽宁 沈阳 110042） 　　【摘 要】目的：研究贝伐单抗联合化疗治疗非小细胞肺癌的疗效，探讨贝伐单抗联合化疗的治疗价值。方法：将92例非鳞非小细胞肺癌患者随机分为治疗组和对照组各46例，对照组采用培美曲塞联合顺铂的化疗方案化疗，治疗组在对照组的基础上加用贝伐单抗治疗，观察两组的治疗效果、生存时间和不良反应发生情况。结果：治疗组有效率47.83%优于对照组的23.91%，chi;2=5.718，p＜0.05，治疗组受益率为91.30%，优于对照组，chi;2=9.200，p＜0.01；治疗组无进展生存期、总生存时间、1年生存率、3年生存率、5年生存率均高于对照组，且均有统计学差异（p＜0.05）；两组不良反应中，治疗组发生略高于对照组，但均无统计学差异（p＞0.05）。结论：贝伐单抗联合一线化疗可从不同作用机制发挥协同治疗的作用，增加化疗对非鳞NSCLC治疗效果，有临床推广价值。 　　【关键词】非小细胞肺癌；贝伐单抗；化疗 　　【中图分类号】R734.2 【文献标识码】B 【文章编号】1003-5028（2015）8-0618-01 　　Clinical Study on the Bevacizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer 　　Zhang Linlin 　　(Internal Medicine 5，Liaoning Province Cancer Hospital, Shenyang, Liaoning, China, 110042) 　　【Abstract】Aim：To study the clinical effect and applicatoin value of Bevacizumab combined with chemotherapy in the treatment of non-small cell lung cancer（NSCLC) . Methods：92 cases of advanced non-squamous NSCLC were divided into the treatment group( n=46 cases) and the control group(n=46 cases)．The control group received chemotherapy (pemetrexed + cisplatin) and the treatment group was gived given bevacizumab + pemetrexed + cisplatin. The therapy effect, total survival time and adverse reaction were observed and compared. Results：The response rate and clinical beneficial rate of the treatment group were =higher than those of =control group with significant differences (chi;2=5.718，9.200，p＜0.05). The progression free survival time, overall survival, one year survival rate, three years survival rate and five years survival rate were higher than those of control group with significant differences (p＜0.05). The adverse reactions incidence rate had no statistical significance between treatment group and control group (p＞0.05). Conclusion：The short-term and long-term efficacy of combined with first-line chemotherapy were superior to first-line chemotherapy in the treatment of advanced non-squamous NSCLC, which could enhance the th